V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Trials Network. [electronic resource]
Producer: 19930915Description: 840-7 p. digitalISSN:- 0021-9738
- AIDS Vaccines -- immunology
- Adult
- Antibodies, Monoclonal -- metabolism
- Antigens, CD -- metabolism
- Binding Sites
- Binding, Competitive
- CD4 Antigens -- metabolism
- Cell Line
- Gene Products, env -- immunology
- HIV Antibodies -- blood
- HIV Envelope Protein gp120 -- metabolism
- HIV Envelope Protein gp160
- HIV-1 -- immunology
- Humans
- Immunoglobulin G -- blood
- Membrane Fusion -- drug effects
- Neutralization Tests
- Protein Precursors -- immunology
- Vaccines, Synthetic -- immunology
- Vaccinia virus -- immunology
No physical items for this record
Publication Type: Clinical Trial; Journal Article; Multicenter Study; Research Support, U.S. Gov't, P.H.S.
There are no comments on this title.
Log in to your account to post a comment.